These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 8163364

  • 1. Perimenstrual migraine: effect of Estraderm TTS and the value of contingent negative variation and exteroceptive temporalis muscle suppression test.
    Smits MG, van der Meer YG, Pfeil JP, Rijnierse JJ, Vos AJ.
    Headache; 1994 Feb; 34(2):103-6. PubMed ID: 8163364
    [Abstract] [Full Text] [Related]

  • 2. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). I. Tolerability, adhesion and efficacy.
    Rozenbaum H, Birkhäuser M, De Nooyer C, Lambotte R, Pornel B, Schneider H, Studd J.
    Maturitas; 1996 Nov; 25(3):161-73. PubMed ID: 8981333
    [Abstract] [Full Text] [Related]

  • 3. Safety and tolerability of short-term preventive frovatriptan: a combined analysis.
    MacGregor EA, Brandes JL, Silberstein S, Jeka S, Czapinski P, Shaw B, Pawsey S.
    Headache; 2009 Oct; 49(9):1298-314. PubMed ID: 19788471
    [Abstract] [Full Text] [Related]

  • 4. Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study.
    MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A.
    Neurology; 2006 Dec 26; 67(12):2159-63. PubMed ID: 17190936
    [Abstract] [Full Text] [Related]

  • 5. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). II. Local skin tolerability.
    Rozenbaum H, Birkhäuser M, De Nooyer C, Lambotte R, Pornel B, Schneider H, Studd J, Thebault J.
    Maturitas; 1996 Nov 26; 25(3):175-85. PubMed ID: 8981334
    [Abstract] [Full Text] [Related]

  • 6. Comparison of pharmacokinetic profiles of a 17 beta-estradiol gel 0.6 mg/g (Gelestra) with a transdermal delivery system (Estraderm TTS 50) in postmenopausal women at steady state.
    Paoletti AM, Pilia I, Nannipieri F, Bigini C, Melis GB.
    Maturitas; 2001 Dec 14; 40(3):203-9. PubMed ID: 11731181
    [Abstract] [Full Text] [Related]

  • 7. Exteroceptive suppression of temporalis muscle activity during migraine attack and migraine interval before and after treatment with sumatriptan.
    Göbel H, Krapat S, Dworschak M, Heuss D, Ensink FB, Soyka D.
    Cephalalgia; 1994 Apr 14; 14(2):143-8. PubMed ID: 8062353
    [Abstract] [Full Text] [Related]

  • 8. Perimenstrual eletriptan prevents menstrual migraine: an open-label study.
    Marcus DA, Bernstein CD, Sullivan EA, Rudy TE.
    Headache; 2010 Apr 14; 50(4):551-62. PubMed ID: 20236337
    [Abstract] [Full Text] [Related]

  • 9. Comparison of contingent negative variation between migraine interval and migraine attack before and after treatment with sumatriptan.
    Göbel H, Krapat S, Ensink FB, Soyka D.
    Headache; 1993 Apr 14; 33(10):570-2. PubMed ID: 8294198
    [Abstract] [Full Text] [Related]

  • 10. [Electrophysiologic investigations in migraine].
    Schoenen J.
    Pathol Biol (Paris); 1992 Apr 14; 40(4):293-304. PubMed ID: 1495813
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine.
    Tuchman M, Hee A, Emeribe U, Silberstein S.
    CNS Drugs; 2006 Apr 14; 20(12):1019-26. PubMed ID: 17140280
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the local tolerability and adhesion of a new matrix system (Menorest) for estradiol delivery with an established transdermal membrane system (Estraderm TTS).
    Erianne JA, Winter L.
    Maturitas; 1997 Mar 14; 26(2):95-101. PubMed ID: 9089558
    [Abstract] [Full Text] [Related]

  • 13. Effective treatment of severe menstrual migraine headaches with gonadotropin-releasing hormone agonist and "add-back" therapy.
    Murray SC, Muse KN.
    Fertil Steril; 1997 Feb 14; 67(2):390-3. PubMed ID: 9022620
    [Abstract] [Full Text] [Related]

  • 14. Scheduled short-term prevention with frovatriptan for migraine occurring exclusively in association with menstruation.
    Silberstein SD, Berner T, Tobin J, Xiang Q, Campbell JC.
    Headache; 2009 Oct 14; 49(9):1283-97. PubMed ID: 19751371
    [Abstract] [Full Text] [Related]

  • 15. Contingent negative variation in migraine: effect of beta blocker therapy.
    Ahmed I.
    Clin Electroencephalogr; 1999 Jan 14; 30(1):21-3. PubMed ID: 9891188
    [Abstract] [Full Text] [Related]

  • 16. Characteristics of menstrual vs nonmenstrual migraine: a post hoc, within-woman analysis of the usual-care phase of a nonrandomized menstrual migraine clinical trial.
    MacGregor EA, Victor TW, Hu X, Xiang Q, Puenpatom RA, Chen W, Campbell JC.
    Headache; 2010 Apr 14; 50(4):528-38. PubMed ID: 20236340
    [Abstract] [Full Text] [Related]

  • 17. Contingent negative variation during migraine attack and interval: evidence for normalization of slow cortical potentials during the attack.
    Kropp P, Gerber WD.
    Cephalalgia; 1995 Apr 14; 15(2):123-8; discussion 78-9. PubMed ID: 7641246
    [Abstract] [Full Text] [Related]

  • 18. Menstrual migraine: a double-blind trial of percutaneous estradiol.
    Dennerstein L, Morse C, Burrows G, Oats J, Brown J, Smith M.
    Gynecol Endocrinol; 1988 Jun 14; 2(2):113-20. PubMed ID: 3055819
    [Abstract] [Full Text] [Related]

  • 19. Disease duration of episodic migraine correlates with modified amplitudes and habituation of contingent negative variation.
    Kropp P, Wallasch TM, Müller B, Meyer B, Darabaneanu S, Bosse C, Keller A, Meyer W, Gerber WD.
    J Neural Transm (Vienna); 2015 Jun 14; 122(6):877-85. PubMed ID: 25432434
    [Abstract] [Full Text] [Related]

  • 20. Prevention of menstrual migraine with perimenstrual transdermal 17-β-estradiol: a randomized, placebo-controlled, double-blind crossover study.
    Almén-Christensson A, Hammar M, Lindh-Åstrand L, Landtblom AM, Brynhildsen J.
    Fertil Steril; 2011 Aug 14; 96(2):498-500.e1. PubMed ID: 21704313
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.